Why the study?
Alveolar beta-2-receptor blockade worsens lung diffusion in HF, an effect that could potentially be mitigated by stimulating alveolar beta-2-receptors.
Does inhaled indacaterol improve lung diffusion and exercise performance in patients with chronic heart failure treated with selective or non-selective beta-blockers?
Does inhaled indacaterol improve lung diffusion and exercise performance in patients with chronic heart failure treated with selective or non-selective beta-blockers?
Inhaled indacaterol is safe in HFrEF patients on beta-blockers but does not improve lung diffusion, though it increases ventilatory response to exercise in those on bisoprolol.
Answers are grounded in this paper and cite their sources.
Alveolar β2-blockade worsens lung diffusion in HF; extends β-blocker pulmonary data and supports indacaterol trials in carvedilol- or bisoprolol-treated patients.
Alveolar β 2 -receptor blockade worsens lung diffusion in heart failure (HF). This effect could be mitigated by stimulating alveolar β 2 -receptors. We investigated the safety and the effects of indacaterol on lung diffusion, lung mechanics, sleep respiratory behavior, cardiac rhythm, welfare, and exercise performance in HF patients treated with a selective (bisoprolol) or a non-selective (carvedilol) β-blocker. Study procedures were performed before and after indacaterol and placebo treatments according to a cross-over, randomized, double-blind protocol in forty-four patients (27 on bisoprolol and 17 on carvedilol). No differences between indacaterol and placebo were observed in the whole population except for a significantly higher VE/VCO 2 slope and lower maximal P ET CO 2 during exercise with indacaterol, entirely due to the difference in the bisoprolol group (VE/VCO 2 31.8 ± 5.9 vs. 28.5 ± 5.6, p < 0.0001 and maximal P ET CO 2 36.7 ± 5.5 vs. 37.7 ± 5.8 mmHg, p < 0.02 with indacaterol and placebo, respectively). In carvedilol, indacaterol was associated with a higher peak heart rate (119 ± 34 vs. 113 ± 30 bpm, with indacaterol and placebo) and a lower prevalence of hypopnea during sleep (3.8 [0.0;6.3] vs. 5.8 [2.9;10.5] events/hour, with indacaterol and placebo). Inhaled indacaterol is well tolerated in HF patients, it does not influence lung diffusion, and, in bisoprolol, it increases ventilation response to exercise.
No takes yet. Share an insight, caveat, or question.
Contini et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: